Encoded secures $275m for Dravet syndrome gene therapy - Pharmaceutical Technology

Proceeds will go towards a pivotal trial of the candidate in paediatric patients. Proceeds will go towards a pivotal trial of the candidate in paediatric patients. Dravet syndrome causes a severe form of epilepsy and long-lasting seizures accompanied by developmental delays. Credit: MAXIMUM ART/Shutterstock.com. Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for Dravet syndrome, with an eye also on initiating clinical trials for another gene therapy candidate in its pipeline. The round was co-led by GV and another healthcare fund, with participation from big investment players such as…

Source: Pharmaceutical Technology